You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on colorectal cancer.
CNBC reports on firms pursuing blood tests to detect early-stage cancer.
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
The group aims to develop a transcriptomic and epigenetic biomarker assay for early detection and relapse monitoring in colorectal cancer patients.
The company plans to submit a companion diagnostic version of its sequencing-based liquid biopsy test Guardant360 to various regulatory bodies.
The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.
In Science this week: circulating tumor DNA to identify colorectal cancer and predict survival, and more.
A Sun-Yat Sen University Cancer Center-led team found circulating tumor DNA methylation patterns could detect colorectal cancer among asymptomatic individuals.
The companies are aiming to use microbial biomarkers to predict the development of precancerous adenomas and carcinomas.
Researchers identified 10 protein-based tumor subtypes across five cancer types, including subtypes representing immune cell features in the tumor microenvironment.
Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.